Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
David H
DH
Cribbs
Michael G
MG
Agadjanyan
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D004195:Disease Models, Animal; D006801:Humans; D007116:Immunization, Passive / Q000379:methods* / Q000639:trends; D016233:Immunotherapy, Active / Q000379:methods* / Q000639:trends
D016229:Amyloid beta-Peptides; D000906:Antibodies